Emergex announces approval to begin Phase I clinical trial of its n…


Emergex announces approval to begin Phase I clinical trial of its
next generation COVID-19 vaccine candidate

  • Synthetic vaccine designed to chief T-Cells to rapidly remove viral-infected cells from the body after infection
  • May offer general immunity against SARS-CoV-1 and all SARS-CoV-2 variants and provide long-lasting immunity that does not require seasonal booster vaccines

Abingdon, Oxon, UK, 15 November 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats by the development of 100% synthetic T Cell priming vaccines today announces that it has received the necessary regulatory approvals to begin a Phase I clinical trial to estimate the safety and tolerability of its vaccine candidate for SARS-CoV-2, the virus which causes COVID-19.

The Phase I trial is a double-blind, randomised and comparator-controlled study of two groups of 13 volunteers at high and low doses. In addition to providing safety and tolerability data, early data on CD8+ T-Cell mediated immune responses as a surrogate of protection against COVID-19 will be provided. The trial will be conducted by Professor Blaise Genton, Principal Investigator, from the Center for dominant Care and Public Health at the University of Lausanne, Switzerland. The first patient is expected to receive their first measure of Emergex vaccine candidate at the start of January 2022.

A Phase I clinical trial (NCT04935801), named naNO-DENGUE, testing Emergex’s Dengue vaccine candidate is currently underway in Switzerland with all patients having received two vaccine doses.

Robin Cohen, Chief Commercial Officer at Emergex Vaccines, commented: Our T Cell priming vaccines may offer meaningful benefits over current COVID-19 vaccines including longer lasting immunity and broader protection against new variants. We are proud to announce the lauching of this trial and look forward to gathering data to sustain the development of this important next generation vaccine.

Professor Blaise Genton, Principal Investigator for the trial from the Center for dominant Care and Public Health (Unisante) at the University of Lausanne, Switzerland commented: Although current COVID-19 vaccines have made meaningful progress in reducing mortality and morbidity challenges nevertheless keep, especially with the development of new variants. This exciting new scientific approach to developing a vaccine against SARS-CoV-2 addresses the need to generate a T-Cell response to elicit long term immunity. We look forward to evaluating the results as when they are obtainable.

Emergex’s vaccines aim to chief naive CD8+ T-Cells to generate virus specific CTLs (CD8+ T-cells/Cytotoxic T Lymphocytes) to kill viral infected cells, preventing viral replication and disease and reducing symptoms and the transmissibility between infected and non-infected individuals. As a consequence, Emergex’s T-Cell priming vaccines have the possible to be more effective in targeting rapidly mutating viruses such as SARS-CoV-2 and eliminate the need for seasonal booster vaccines in comparison to current vaccine technologies, which chiefly rely on an antibody immune response. In addition, Emergex’s vaccine is raised against antigens that are highly conserved so may provide cross reactive immunity to SARS-CoV-1 infection and all SARS-CoV-2 variants and strains of the virus, offering general immune protection from two pandemic viruses in one vaccine.

Emergex vaccines have been designed to be administered via the skin using micro needles and to be stable at ambient room temperature for beyond three months, easing rapid and efficient dispensing across the world and making administration of the vaccine more patient friendly.

Ends –

For further information, please contact:

About Emergex

Emergex, a biotechnology company headquartered in Abingdon, UK, with an operating subsidiary in Doylestown, Pennsylvania, USA, is pioneering the development of synthetic vaccines which chief the T-Cell immune response to address some of the world’s most immediate health threats such as COVID-19, Dengue Fever, Zika, Ebola, pandemic flu and serious intra-cellular bacterial infections.

These set-point vaccines modify the initial immune position of recipients in a way that ‘primes’ their immune systems to recognise later infectious agents much like a natural infection would do, preventing an acute or harsh manifestation of the disease.

Emergex uses a synthetic nano gold carrier system to deliver a specific set of peptides to the body’s immune system, generating a strong T-Cell response that has the possible to provide a rapid and general immune response that may last for decades.

The Company has a growing pipeline of vaccine candidates. The most progressive development programmes are a vaccine for Dengue Fever. The vaccine technology offers the possible for cross-reactive immune responses for other Flaviviruses such as the Zika and Yellow Fever viruses. Emergex has programmes in development for a universal Influenza vaccine, a universal Filovirus vaccine (including viruses such as Ebola and Marburg) and discovery programmes for a Yellow Fever Booster vaccine, a therapeutic Hepatitis B vaccine and a Chikungunya vaccine.

Emergex has partnered with the Institute of Molecular and Cell Biology (IMCB) of Singapore to develop a vaccine for the emerging threat of Hand, Foot and Mouth (HFM) disease. The Company also has a collaboration in place with Brazil-based Bio-Manguinhos/Fiocruz for the development of several vaccine candidates, including a possible vaccine for COVID-19.

Find out more online at www.emergexvaccines.com.

The content is by GlobeNewswire. DKODING Media is not responsible for the content provided or any links related to this content. DKODING Media is not responsible for the correctness, topicality or the quality of the content.

Click: See details

Leave a Reply